Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Oral Oncol. 2015 Jan 13;51(4):376–382. doi: 10.1016/j.oraloncology.2014.12.011

Figure 1.

Figure 1

Figure 1

A. Waterfall plots of response rates after cetuximab (Arm A, blue bar) and cetuximab+sorafenib (Arm B, red bar). Red star *: progressive disease, Black +: p16 immunohistochemical staining positive. B. Overall survival: Kaplan-Meier plot comparing cetuximab (Arm A, blue line) and cetuximab+sorafenib (Arm B, red line). C. Progression-free survival: Kaplan-Meier plot comparing cetuximab (Arm A, blue line) and cetuximab+sorafenib (Arm B, red line).